title: Experimental study of the efficiency of impaza on the model of chronic aseptic prostatic inflammation.
abstract: We compared the efficacy of Impaza (antibodies against endothelial NO-synthase in ultra-low doses) and Serenoa repens on the rat model of chronic aseptic prostatic inflammation. Administration of Serenoa repens in a dose of 50 mg/kg for 1.5 months prevented the development of prostate sclerosis and increased luminal area, but did delay the development of atrophic processes. In animals treated with Impaza (3 ml/kg for 1.5 months), atrophic changes in the prostate gland were practically absent. These findings indicate that Impaza can be used in complex therapy of abacterial prostatitis.
authors: Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia.
authors: T G
authors: TG
authors: Borovskaya
authors: T I
authors: TI
authors: Fomina
authors: A V
authors: AV
authors: Pakhomova
authors: L A
authors: LA
authors: Ermolaeva
authors: M E
authors: ME
authors: Poluektova
authors: E S
authors: ES
authors: Zhavbert
authors: Ju L
authors: JL
authors: Dugina
authors: I A
authors: IA
authors: Kheifets
authors: O I
authors: OI
authors: Epstein
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D007172:Erectile Dysfunction; D008297:Male; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010936:Plant Extracts / Q000627:therapeutic use; D011472:Prostatitis / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D028024:Serenoa / Q000737:chemistry
chemical_list: D000906:Antibodies; C534505:IMPAZA; D010936:Plant Extracts; D052250:Nitric Oxide Synthase Type III